TBPH - Theravance Biopharma, Inc.
IEX Last Trade
9.59
0.010 0.104%
Share volume: 3,502
Last Updated: Fri 27 Dec 2024 06:30:06 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.96%
PREVIOUS CLOSE
CHG
CHG%
$9.58
0.01
0.10%
Fundamental analysis
23%
Profitability
15%
Dept financing
17%
Liquidity
75%
Performance
20%
Performance
5 Days
0.61%
1 Month
6.60%
3 Months
22.21%
6 Months
17.12%
1 Year
-12.37%
2 Year
-12.83%
Key data
Stock price
$9.59
DAY RANGE
$9.57 - $9.89
52 WEEK RANGE
$7.76 - $11.71
52 WEEK CHANGE
-$12.91
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Rick E. Winningham
Region: US
Website: theravance.com
Employees: 110
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: theravance.com
Employees: 110
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Theravance Biopharma, Inc. discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD) Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor.
Recent news